Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | IDE | P14735 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11383597 | 0.84 | HTR1A (0.47) | MITFSLC6A4HTR1AMAPTHTR2C | |
| SCHEMBL1579802 | 0.83 | SIGMAR1 (0.50) | MITFSLC6A4NR1H2NR1H3MEN1 | |
| SCHEMBL11464906 | 0.82 | HTR1A (0.47) | MITFHTR1AMAPTHTR2CIDE | |
| SCHEMBL21105516 | 0.78 | RORC (0.46) | MITFSLC6A4SIGMAR1 | |
| SCHEMBL16644677 | 0.78 | RORC (0.46) | MITFSLC6A4SIGMAR1 | |
| SCHEMBL31612476 | 0.76 | SIGMAR1 (0.45) | MITFSLC6A4MEN1KMT2AALDH1A1 | |
| SCHEMBL11706639 | 0.76 | MEN1 (0.48) | SLC6A4MEN1KMT2AALDH1A1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL27831417 | 0.76 | ALDH1A1 (0.49) | MITFSLC6A4MAPTLMNASMN1; SMN2 | |
| SCHEMBL27831282 | 0.75 | ALDH1A1 (0.48) | MITFSLC6A4MAPTLMNASMN1; SMN2 | |
| SCHEMBL17505008 | 0.74 | NR1H2 (0.55) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101887-B2 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | NEUROGEN CORPORATION (US) | 2005-10-27 | — | — | US | disclosed |
| EP-0960106-B1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORP (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040083447-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-04-29 | — | — | US | disclosed |
| US-6656943-B2 | In the treatment or prevention of psychotic disorders such as schizophrenia psychotic depression, mania and other central nervous system diseases | NEUROGEN CORPORATION | 2003-12-02 | — | — | US | disclosed |
| US-20030119851-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-06-26 | — | — | US | disclosed |
| US-6426347-B2 | FOR PREVENTION OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION | 2002-07-30 | — | — | US | disclosed |
| US-20020007064-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | THURKAUF ANDREW (US) | 2002-01-17 | — | — | US | disclosed |
| US-6172229-B1 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0960106-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5859246-A | TREATING NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998033784-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | DRD2, DRD4, HTR2C | MITF 1158/4885SLC6A4 94/4885HTR1A 6/4885 |
| US-20020007064-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | HTR2C, GRIN2C, HTR1A | MITF 1246/4885SLC6A4 117/4885HTR1A 3/4885 |
| US-20030119851-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | HTR2C, GRIN2C, HTR1A | MITF 1246/4885SLC6A4 117/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.